These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 18384109

  • 1. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro.
    Schmid U, Stopper H, Heidland A, Schupp N.
    Diabetes Metab Res Rev; 2008; 24(5):371-7. PubMed ID: 18384109
    [Abstract] [Full Text] [Related]

  • 2. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha.
    Wu S, Ren J.
    Neurosci Lett; 2006 Feb 13; 394(2):158-62. PubMed ID: 16260089
    [Abstract] [Full Text] [Related]

  • 3. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes.
    Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D.
    Diabetes Care; 2006 Sep 13; 29(9):2064-71. PubMed ID: 16936154
    [Abstract] [Full Text] [Related]

  • 4. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.
    Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M.
    Nat Med; 2003 Mar 13; 9(3):294-9. PubMed ID: 12592403
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats.
    Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Köpcke W, Sauerland C, Bretzel RG, Federlin KF.
    Exp Clin Endocrinol Diabetes; 2001 Mar 13; 109(6):330-6. PubMed ID: 11571671
    [Abstract] [Full Text] [Related]

  • 6. Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes.
    Beltramo E, Nizheradze K, Berrone E, Tarallo S, Porta M.
    Diabetes Metab Res Rev; 2009 Oct 13; 25(7):647-56. PubMed ID: 19768736
    [Abstract] [Full Text] [Related]

  • 7. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose.
    Beltramo E, Berrone E, Buttiglieri S, Porta M.
    Diabetes Metab Res Rev; 2004 Oct 13; 20(4):330-6. PubMed ID: 15250036
    [Abstract] [Full Text] [Related]

  • 8. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis.
    Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, Campesi I, Invernici G, Spillmann F, Ward K, Madeddu P.
    Diabetologia; 2006 Feb 13; 49(2):405-20. PubMed ID: 16416271
    [Abstract] [Full Text] [Related]

  • 9. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine.
    Beltramo E, Berrone E, Tarallo S, Porta M.
    Diabetes Metab Res Rev; 2009 Sep 13; 25(6):566-76. PubMed ID: 19593734
    [Abstract] [Full Text] [Related]

  • 10. Oxidative DNA damage protection and repair by polyphenolic compounds in PC12 cells.
    Silva JP, Gomes AC, Coutinho OP.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):50-60. PubMed ID: 18996367
    [Abstract] [Full Text] [Related]

  • 11. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications.
    Beltramo E, Berrone E, Tarallo S, Porta M.
    Acta Diabetol; 2008 Sep 28; 45(3):131-41. PubMed ID: 18581039
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein.
    Liu Q, Wang G, Zhou G, Tan Y, Wang X, Wei W, Liu L, Xue W, Feng W, Cai L.
    Toxicol Lett; 2009 Dec 15; 191(2-3):314-20. PubMed ID: 19808082
    [Abstract] [Full Text] [Related]

  • 13. The multifaceted therapeutic potential of benfotiamine.
    Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A.
    Pharmacol Res; 2010 Jun 15; 61(6):482-8. PubMed ID: 20188835
    [Abstract] [Full Text] [Related]

  • 14. 3,4-dihydroxybenzaldehyde purified from the barley seeds (Hordeum vulgare) inhibits oxidative DNA damage and apoptosis via its antioxidant activity.
    Jeong JB, Hong SC, Jeong HJ.
    Phytomedicine; 2009 Jan 15; 16(1):85-94. PubMed ID: 19022639
    [Abstract] [Full Text] [Related]

  • 15. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats.
    Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ.
    Ann N Y Acad Sci; 2005 Jun 15; 1043():777-83. PubMed ID: 16037305
    [Abstract] [Full Text] [Related]

  • 16. New approaches for the treatment of genomic damage in end-stage renal disease.
    Schupp N, Schmid U, Heidland A, Stopper H.
    J Ren Nutr; 2008 Jan 15; 18(1):127-33. PubMed ID: 18089459
    [Abstract] [Full Text] [Related]

  • 17. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors.
    Schupp N, Schinzel R, Heidland A, Stopper H.
    Ann N Y Acad Sci; 2005 Jun 15; 1043():685-95. PubMed ID: 16037294
    [Abstract] [Full Text] [Related]

  • 18. Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity.
    Arbillaga L, Azqueta A, Ezpeleta O, López de Cerain A.
    Mutagenesis; 2007 Jan 15; 22(1):35-42. PubMed ID: 17130176
    [Abstract] [Full Text] [Related]

  • 19. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients.
    Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A, Stopper H.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep 15; 378(3):283-91. PubMed ID: 18509620
    [Abstract] [Full Text] [Related]

  • 20. Membrane gamma-glutamyl transferase activity promotes iron-dependent oxidative DNA damage in melanoma cells.
    Corti A, Duarte TL, Giommarelli C, De Tata V, Paolicchi A, Jones GD, Pompella A.
    Mutat Res; 2009 Oct 02; 669(1-2):112-21. PubMed ID: 19505483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.